Immunization, Vaccines and Biologicals


Polio (poliomyelitis) is a highly infectious disease caused by a virus. It invades the nervous system and can cause irreversible paralysis in a matter of hours. Polio is spread through person-to-person contact. When a child is infected with wild poliovirus, the virus enters the body through the mouth and multiplies in the intestine. It is then shed into the environment through the faeces where it can spread rapidly through a community, especially in situations of poor hygiene and sanitation. If a sufficient number of children are fully immunized against polio, the virus is unable to find susceptible children to infect, and dies out.

Most infected people (90%) have no symptoms or very mild symptoms and usually go unrecognized. In others, initial symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs.

There is no cure for polio, only treatment to alleviate the symptoms. Heat and physical therapy is used to stimulate the muscles and antispasmodic drugs are given to relax the muscles. While this can improve mobility, it cannot reverse permanent polio paralysis.

Polio can be prevented through immunization. Polio vaccine, given multiple times, almost always protects a child for life. The development of effective vaccines to prevent paralytic polio was one of the major medical breakthroughs of the 20th century. With the development and evaluation of bivalent oral polio vaccine in 2009, the Global Polio Eradication Initiative now has an armory of five different vaccines to stop polio transmission:

  • Inactivated polio vaccine (IPV) – protects against poliovirus types 1, 2, and 3
  • Trivalent oral polio vaccine (tOPV) – protects against poliovirus types 1, 2, and 3
  • Bivalent oral polio vaccine (bOPV) – protects against poliovirus types 1, and 3
  • Monovalent oral polio vaccines (mOPV1 and mOPV3) – protect against poliovirus type 1 and type 3, respectively

If enough people in a community are immunized, the virus will be deprived of susceptible hosts and will die out. High levels of vaccination coverage must be maintained to stop transmission and prevent outbreaks occurring.

In May 2012, the World Health Assembly declared the completion of polio eradication a programmatic emergency for global public health and the Polio Eradication and Endgame Strategic Plan 2013-2018 was developed and, in November 2012, endorsed by SAGE. Under objective 2 of the Eradication and Endgame Plan, at least one dose of inactivated poliomyelitis vaccine (IPV) will be introduced into all routine immunization programmes globally, after which trivalent oral polio vaccines (tOPV) will be replaced with bivalent (bOPV) in all OPV-using countries – setting the stage for the eventual withdrawal of all OPV.

Since then, SAGE has been reviewing progress on the country readiness criteria for tOPV withdrawal, including the following:

  • Introduction of at least one dose of inactivated poliovirus vaccine into routine immunization;
  • Access to a bivalent oral polio vaccine that is licensed for routine immunization;
  • Implementation of surveillance and response protocols for type 2 poliovirus (including constitution of a stockpile of monovalent oral polio vaccine type 2);
  • Completion of phase 1 poliovirus containment activities, with appropriate handling of residual type 2 materials; and
  • Verification of global eradication of wild poliovirus type 2.

In April 2015, SAGE concluded that progress towards elimination of persistent cVDPV2 was on track, and recommended that all countries and GPEI should plan firmly for April 2016 as the designated date for withdrawal of OPV2. SAGE specified that it would consider delaying OPV2 withdrawal only if the Working Group reports in October 2015 that the assessed risk of persistent cVDPV2 transmission is high. Also, in May 2015, the World Health Assembly adopted a resolution to stop polio and commit towards preparations for the phased withdrawal of oral polio vaccines starting with the withdrawal of OPV2 in April 2016, in the path towards achieving polio eradication.

See more at: IPV Introduction, OPV Withdrawal and Routine Immunization Strengthening

In the new Eradication and Endgame strategy, research is a vital component of the Global Polio Eradication Initiative, providing the necessary evidence to guide the final steps to a lasting polio-free world and beyond. The Global Polio Eradication Initiative coordinates and supports an extensive program of research from a wide range of core scientific disciplines. The research program has two broad objectives:

  • to identify, develop and evaluate new tools and tailored approaches to maximize the impact of eradication efforts
  • to inform long-term policy for the post-eradication era.

See more at: Polio eradication research

WHO position papers

Disease burden and surveillance

Vaccine topics

SAGE recommendations for polio

Further information

Page last updated: 21 September 2015


30 September 2015

22 September 2015

Request for proposals: micro-needle patch usability & acceptability evaluation